Invoke Capital is a very different type of technology investor. Founded by celebrated technologist Dr Mike Lynch, Invoke invests in and supports world-leading fundamental technology businesses emerging across Europe.
Since 2012, Invoke has been instrumental in developing and scaling prominent UK tech companies from innovative start-ups out of Cambridge University into global businesses.
To date the value of Invoke's investment in its portfolio is more than $500m. Its portfolio companies include Darktrace, a world-leading cyber AI company that employs more than 1,500 people globally, and Luminance, an award-winning machine learning platform for the legal industry. Find out more about Invoke's portfolio here.
Dr Mike Lynch OBE FREng FRS
Founder, Invoke Capital
Referred to as the UK's answer to Bill Gates, Mike is a celebrated technologist, having pioneered three of the biggest success stories in UK tech – Autonomy, Blinkx and Darktrace. Dr Lynch read Natural Sciences at Cambridge University, where he also gained a Ph.D. and held a research fellowship in adaptive pattern recognition. In 1996 he founded Autonomy and served as its CEO for 15-years. During this time Autonomy became one of the UK's most successful technology companies on the FTSE100. It was acquired by HP for $11 billion in 2011.
The Latest From Invoke Insights
The UK's post-Brexit opportunity in tech
With Brexit done, the COVID-19 vaccine being rolled out and the country playing host to the G7 Summit and COP26; 2021 marks the beginning of a new era for the UK. In this blog post, Dr Mike Lynch discusses why this must be an era of technology, science and innovation.
Mike Lynch: "Post-Brexit, we have the freedom to move faster and go further in developing regulatory frameworks that allow fundamental technologies to flourish commercially in the UK. If these are at the heart of the government’s agenda for 2021, I have no doubt the UK will fulfil its goal of becoming a science."
In conversation with Dr Mike Lynch OBE and Matthew Gould, British civil servant and CEO of NHSX.
2020 has been a year that not many people would have anticipated turning out the way it has, and it has put a huge focus on the NHS – both celebrating the staff on the frontline, but also showing its difficulties. And while in the corporate world we have seen an acceleration in the adoption of digital technologies, medicine is also one of the sectors in which emerging technologies are having the most profound effect.
In this podcast, Dr Lynch and Matthew Gould, CEO of NHSX, a joint unit between the Department for Health and Social Care and NHS England, set up to ensure that staff and patients have the technology they need, discuss the impact of the Covid-19 pandemic, the rise of personalised medicine and which technologies are going to have the biggest impact on our health.
Dr Mike Lynch on which emerging technologies in science and tech the UK can capitalise on.
What is really going to change the world in tech? We're now living in a world in which a lot of our day-to-day tasks are being done by technology. In this video, Dr Lynch discusses the impact that advanced technologies such as artificial intelligence and quantum computing are having on peoples' lives, commerce and the economy.
Mike Lynch: "One of the phrases that you can't avoid now if you read the paper is Artificial Intelligence. A lot of what is out there is not very well informed extrapolation. But putting that aside, underneath that there is something absolutely fundamental that is going to change most aspects of our world."
Read more insights here.